@FierceMedDev: Myriad's multigene predictive cancer test shows utility in new trial. FierceDiagnostics article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli. Story | Follow @VarunSaxena2
@MichaelGFierce: ICYMI: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery article | Follow @MichaelGFierce
@EmilyWFierce: Case hedges bets on brain device developer with a smartphone-based system for traumatic brain injuries. More from Bloomberg | Follow @EmilyWFierce
> Research published in Heart Rhythm suggests that monitoring sex hormone levels can predict a patient's risk of suffering sudden cardiac arrest. Story
> Stereotaxis received FDA clearance to market its second Vdrive robotic navigation system. Story
> AcuFocus raised an additional $21 million from its existing investors as it awaits FDA approval for the vision loss treatment, Kamra device. Story
> AOL co-founder Steve Case, along with his wife Jean, invested in BrainScope's handheld brain trauma assessment device as part of a wave of altruistic investment. Story
Biotech News
@FierceBiotech: EuroBiotech Report: AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015, more. More | Follow @FierceBiotech
@JohnCFierce: ICYMI - Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. Report | Follow @JohnCFierce
@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce
> Recro tanks after hitting the brakes on its lead pain drug. Story
> OncoMed gets back on track as FDA clears another clinical hold. Article
> Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. News
Pharma News
@FiercePharma: Top-read in FiercePharmaManufacturing Thursday: $ACT production not meeting demand for new version of Alzheimer's drug. Article | Follow @FiercePharma
@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. More | Follow @EricPFierce
@CarlyHFierce: Legendary Genentech CEO Levinson cuts last ties with Roche. Story | Follow @CarlyHFierce
> Merck's melanoma 'game-changer' Keytruda likely to bolster drug pricing debate. Article
> Feds intercept pharmacist linked to meningitis outbreak as he headed to Hong Kong. Story